卡维地洛对比内镜套扎术用于食管静脉曲张出血二级预防的随机对照试验长期随访
该研究对2006至2011年间因食管静脉曲张出血随机接受卡维地洛或内镜套扎术(EBL)的64例肝硬化患者进行长期随访至2020年4月。符合方案分析显示卡维地洛组长期生存改善(p=0.005,HR 3.083,95%CI 1.397-6.809),肝病相关死亡更少(0% vs 22.57%),失代偿性肝病住院更少(12% vs 64.29%),静脉曲张再出血率无统计学显著差异。
要点
- 符合方案分析中卡维地洛组长期生存优于EBL组(p=0.005,HR 3.083,95%CI 1.397-6.809)。
- 卡维地洛组肝病相关死亡0% vs EBL组22.57%(p=0.013,OR ∞,95%CI 1.565-∞)。
- 卡维地洛组失代偿性肝病住院12% vs EBL组64.29%(p=0.0002,OR 13.2,95%CI 3.026-47.23)。
核心结论
- 在肝硬化食管静脉曲张出血患者中,卡维地洛使用与生存获益、更少肝病相关死亡及更少失代偿性肝病住院相关。
- 需进一步研究验证该发现。
研究设计与样本
- 索引研究为随机对照试验,2006至2011年间随机分配64例食管静脉曲张出血的肝硬化患者接受卡维地洛或内镜套扎术(EBL)。
- 随访至2020年4月,通过审查电子病历进行。
- 主要结局为生存。
主要发现
- 随访期间33例中26例接受卡维地洛,31例中28例参加规律EBL治疗。
- 所有入组患者中位随访天数1459天(SE=281.74)。
- 意向性治疗分析中,卡维地洛组生存改善呈趋势(p=0.09)。
- 符合方案分析中,卡维地洛组长期生存改善(p=0.005,HR 3.083,95%CI 1.397-6.809),肝病相关死亡更少(0% vs 22.57%,p=0.013,OR ∞,95%CI 1.565-∞),失代偿性肝病住院更少(12% vs 64.29%,p=0.0002,OR 13.2,95%CI 3.026-47.23)。
- 静脉曲张再出血率无统计学显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需进一步研究验证该发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Carvedilol reduces rates of variceal bleeding and rebleeding by lowering portal pressure. However, an associated pleiotropic survival benefit has been proposed. We aimed to assess long-term survival in a cohort of patients previously randomised to receive either carvedilol or endoscopic band ligation (EBL) following oesophageal variceal bleeding (OVB). METHODS: The index study randomised 64 cirrhotic patients with OVB between 2006 and 2011 to receive either carvedilol or EBL. Follow-up was undertaken to April 2020 by review of electronic patient records. The primary outcome was survival. Other outcomes including variceal rebleeding and liver decompensation events were compared. RESULTS: 26 out of 33 participants received carvedilol in the follow-up period and 28 out of 31 attended regular EBL sessions. The median number of follow-up days for all patients recruited was 1459 (SE = 281.74). On the intention to treat analysis, there was a trend towards improved survival in the carvedilol group (p = 0.09). On per-protocol analysis, carvedilol use was associated with improved long-term survival (p = 0.005, HR 3.083, 95% CI 1.397-6.809), fewer liver-related deaths (0% vs 22.57%, p = 0.013, OR ∞, 95%CI 1.565-∞) and fewer admissions with decompensated liver disease (12% vs 64.29%, p = 0.0002, OR 13.2, 95% CI 3.026-47.23) compared to the EBL group. There was no statistically significant difference in variceal rebleeding rates. CONCLUSION: Following OVB in cirrhotic patients, carvedilol use is associated with survival benefit, fewer liver-related deaths and fewer hospital admissions with decompensated liver disease. Further studies are needed to validate this finding.
引用
- Dunne PDJ, Young D, Chuah CS, et al. Carvedilol versus endoscopic band ligation for secondary prophylaxis of variceal bleeding-long-term follow-up of a randomised control trial. Aliment Pharmacol Ther. 2022. PMID: 35322892. doi:10.1111/apt.16901
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。